priors.science/reviews/systemic-lupus-erythematosus

Systemic Lupus Erythematosus

The current evidence on 28 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

28claims tracked
272primary papers reviewed
10 Aug 2026latest evidence review
Weeklyre-scored against new papers
13 Established · 12 Likely · 3 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Systemic lupus erythematosus is independently associated with a 3-to-5-fold increased risk of premature atherosclerosis and cardiovascular events beyond the contribution of traditional cardiovascular risk factors.SLE CVDEstablished92%12
Hydroxychloroquine reduces the rate of disease flares and should be prescribed to all patients with systemic lupus erythematosus unless contraindicated.SLE HCQEstablished92%13
Glucocorticoid use exceeding 7.5 mg/day prednisone equivalent for sustained periods is independently associated with accelerated organ damage accrual in SLE, including cardiovascular, metabolic, and musculoskeletal damage.SLE GCEstablished90%9
Combination low-dose aspirin and heparin (LMWH or UFH) reduces pregnancy loss in antiphospholipid syndrome complicating SLE, compared with aspirin alone or no treatment.SLE PregEstablished89%17
Belimumab reduces disease activitySLE BLMEstablished88%11
Hydroxychloroquine use is independently associated with improved long-term survival in systemic lupus erythematosus.SLE HCQEstablished88%13
Mycophenolate mofetil achieves equivalent or superior induction remission rates compared to intravenous cyclophosphamide for proliferative lupus nephritis with a more favourable toxicity profile.SLE LNEstablished88%12
Hydroxychloroquine continuation during pregnancy reduces SLE disease flares without harming fetal outcomes, and its use is recommended for all pregnant SLE patients.SLE PregEstablished88%14
Voclosporin added to mycophenolate mofetil and low-dose steroids significantly improves complete renal response rates in active proliferative or membranous lupus nephritis compared with standard of care alone.SLE VocEstablished87%15
Anifrolumab reduces cutaneous lupus disease activity (CLASI score) and is effective for skin-predominant SLE manifestations.SLE AniEstablished85%17
Belimumab improves lupus nephritis outcomesSLE BLMEstablished85%14
Reducing hydroxychloroquine dosing to ≤5 mg/kg real body weight reduces retinal toxicity risk without significantly increasing flare rates in patients with stable low disease activity.SLE HCQEstablished85%15
Achieving lupus low disease activity state (LLDAS) for at least 50% of follow-up time is associated with significantly reduced damage accrual and improved quality of life compared with persistent active disease.SLE LdaEstablished85%20
Mycophenolate mofetil is superior to azathioprine for maintenance therapy of lupus nephritis, reducing treatment failure and renal relapse.SLE LNLong-standingLikely84%12
Anifrolumab reduces SLE disease activity across organ domains compared with placebo in patients with moderate-to-severe disease on standard background therapy, with particular efficacy for cutaneous and musculoskeletal manifestations.SLE AniLikely83%19
Obinutuzumab added to standard therapy significantly improves complete renal response rates in active proliferative lupus nephritis compared with placebo plus standard therapy.SLE ObiLikely79%16
Voclosporin maintains renal remission benefit at 2 years without significant cumulative loss of eGFR compared with placebo, supporting a favourable long-term renal safety profile.SLE VocLikely78%17
Multitarget therapy combining mycophenolate mofetil, a calcineurin inhibitor (tacrolimus), and low-dose steroids achieves higher complete renal remission rates at 24 weeks than cyclophosphamide monotherapy for lupus nephritis induction.SLE LNLikely77%13
Add-on therapy with belimumab or anifrolumab enables glucocorticoid tapering in SLE patients who would otherwise require sustained moderate doses, reducing cumulative steroid exposure.SLE GCLikely75%18
Upadacitinib 30 mg daily significantly improves SLE disease activity and reduces flares compared with placebo in a Phase 2 trial, establishing efficacy signal for JAK1 inhibition in SLE.SLE JAKLikely75%18
Hydroxychloroquine use is associated with reduced risk of thrombotic events, cardiovascular events, and antiphospholipid antibody-mediated thrombosis in SLE patients.SLE CVDLikely73%13
Persistently elevated anti-double-stranded DNA antibodies and low complement levels identify SLE patients with higher disease activity burden and predict those most likely to benefit from escalation to biologic therapy.SLE LdaLikely73%14
Hydroxychloroquine whole-blood concentration monitoring identifies non-adherent patients and predicts flare risk, with levels below 500 ng/mL associated with significantly higher flare rates.SLE HCQLikely72%12
Early complete renal response predicts long-term outcomeSLE LNLong-standingLikely71%10
High interferon gene signature score at baseline enriches for response to anifrolumab, with IFN-high patients showing consistently larger treatment benefits than IFN-low patients.SLE AniLikely70%19
Early belimumab predicts better remissionSLE BLMUncertain65%14
Obinutuzumab effective after rituximab failureSLE ObiLong-standingUncertain55%12
Baricitinib 4 mg does not achieve statistically significant SRI-4 response versus placebo in the overall SLE population across Phase 3 trials, though clinically meaningful benefits emerge in high-disease-activity subgroups.SLE JAKUncertain52%19
Track Systemic Lupus Erythematosus.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.